P299. Intranasal Esketamine Versus Intravenous Ketamine: An Observational Study Comparing the Efficacy and Tolerability of Two Novel 'Standard of Care' Treatments for Treatment Resistant Depression

Gilmar Gutierrez,Jennifer Swainson,Joshua Rosenblat,Rudolf Uher,Emily Hawken,Gustavo Vazquez

doi:10.1016/j.biopsych.2022.02.535

P299. Intranasal Esketamine Versus Intravenous Ketamine: An Observational Study Comparing the Efficacy and Tolerability of Two Novel 'Standard of Care' Treatments for Treatment Resistant Depression

Gilmar Gutierrez, Jennifer Swainson + Show 4 more

https://doi.org/10.1016/j.biopsych.2022.02.535

Copy DOI

Journal: Biological psychiatry

Publication Date: Apr 28, 2022

Affiliation: Queen's University, University of Alberta, University of Toronto, Dalhousie University

#Management Of Treatment Resistant Depression #Treatment Resistant Depression + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Low dose Ketamine treatment has been studied as a novel alternative to manage treatment resistant depression (TRD) in patients with major depressive disorders (MDD) . The objective of this research study is to compare the efficacy and tolerability of IV Ketamine vs. IN Esketamine in the management of TRD in naturalistic clinical practice.

Full Text